Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summit

11/30/2021 | 07:01am EST

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation is scheduled for Tuesday, December 7, 2021 at 2:40 p.m. ET / 11:40 a.m. PT.

A live webcast of the presentation will be available from the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after the event.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

ę Business Wire 2021
01/20Spectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Co..
01/06SPECTRUM PHARMACEUTICALS : Announces New Strategic Investment by Hanmi Pharmaceutical - Fo..
01/06SPECTRUM PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Unregistered Sa..
01/05Spectrum Pharmaceuticals to Cut 30% of Staff, Prioritize Late-Stage Programs in Restruc..
01/05Spectrum Pharmaceuticals Announces Strategic Restructuring
01/05Spectrum Pharmaceuticals Announces Strategic Restructuring
01/04Spectrum Pharmaceuticals to Get $20 Million Equity Investment from Hanmi Pharmaceutical
01/04Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
01/04Spectrum Pharmaceuticals, Inc. announced that it expects to receive $20 million in fund..
2021SPECTRUM PHARMACEUTICALS, INC.(NASDA : SPPI) dropped from S&P Biotechnology Select Industr..
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -152 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,97x
Yield 2021 -
Capitalization 163 M 163 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 4,55x
Nbr of Employees 176
Free-Float -
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,95 $
Average target price 5,75 $
Spread / Average Target 508%
EPS Revisions
Managers and Directors
Thomas J. Riga President, Chief Executive Officer & Director
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
William L. Ashton Chairman
Francois Lebel Chief Medical Officer
Lyndah K. Dreiling Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592